• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Mesenchymal Stem Cells: The Potential Therapeutic Cell Therapy to Reduce Brain Stroke Side Effects
【24h】

Mesenchymal Stem Cells: The Potential Therapeutic Cell Therapy to Reduce Brain Stroke Side Effects

机译：间充质干细胞：减少脑卒中副作用的潜在治疗细胞疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tissue plasminogen activator (tPA) is the gold standard treatment for ischemic stroke in the time window of 3-4.5 hours after the onset of symptoms. However, tPA administration is associated with inflammation and neurotoxic effects. Mesenchymal stem cells (MSC)-based therapy is emerging as a promising therapeutic strategy to control different inflammatory conditions. This project was designed to examine the protective role of MSC administration alone or in combination with royal jelly (RJ) five hours after stroke onset. The mice model of middle cerebral artery occlusion (MCAO) was established and put to six groups, including intact (healthy mice without stroke), control (untreated stroke), treated with mouse MSC (mMSC), Sup (conditioned medium), RJ and combination of mMSC and RJ (mMSC/RJ). Thereafter, behavioral functions, serum and brain (in both infarcted and non-infarcted tissues) levels of interleukin (IL)-1 beta , IL-4, IL-10, tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) the sizes of brain infarction have been determined in the groups. Administration of mMSC and mMSC/RJ significantly improved the behavioral functions when compared to the controls. mMSC, RJ and mMSC/RJ significantly decreased the infarcted volumes. RJ and mMSC/RJ, but not mMSC, significantly decreased the brain edema. The infarction increased the serum levels of the cytokines, except TNF-alpha, and treatment with mMSC, Sup and RJ reduced serum levels of the pro-inflammatory cytokines. mMSC reduced IL-1 beta in the non-infarcted brain tissue. To conclude, data revealed that using mMSC/RJ combination significantly reduced stroke side effects, including brain edema and serum levels of pro-inflammatory cytokines, and suggested that combination therapy of MSCs with RJ may be considered as an effective stroke therapeutic strategy.
机译：组织型纤溶酶原激活剂（tPA）是在症状出现后3-4.5小时内治疗缺血性中风的金标准。然而，tPA给药与炎症和神经毒性作用有关。以间充质干细胞（MSC）为基础的治疗正在成为控制不同炎症状态的一种有前途的治疗策略。该项目旨在研究MSC单独或与蜂王浆（RJ）联合用药在中风发病五小时后的保护作用。建立小鼠大脑中动脉闭塞（MCAO）模型，分为6组，分别为正常组（无脑卒中的健康小鼠）、对照组（未经治疗的脑卒中）、小鼠MSC（mMSC）、Sup（条件培养基）、RJ及mMSC和RJ联合治疗组（mMSC/RJ）。此后，对两组患者的行为功能、血清和大脑（在梗死和非梗死组织中）白细胞介素-1β、白细胞介素-4、白细胞介素-10、肿瘤坏死因子-α（TNF-α）和干扰素-γ（IFN-γ）水平以及脑梗塞的大小进行了测定。与对照组相比，服用mMSC和mMSC/RJ显著改善了行为功能。mMSC、RJ和mMSC/RJ显著降低梗死体积。RJ和mMSC/RJ（而非mMSC）可显著降低脑水肿。梗死增加了血清中除TNF-α外的细胞因子水平，而mMSC、Sup和RJ治疗降低了血清中促炎细胞因子水平。mMSC降低非梗死脑组织中的IL-1β。总之，数据显示，使用mMSC/RJ联合疗法可显著减少中风的副作用，包括脑水肿和血清促炎细胞因子水平，并表明MSCs与RJ联合疗法可被视为一种有效的中风治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号